The treatment of varicella-zoster virus infection and its complications

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 5, 2009, Pages 797-812

  Partridge, David G ^a   McKendrick, Michael W ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Aciclovir; Analgesia; Brivudin; Cidofovir; Corticosteroids; Famciclovir; Foscarnet; Gabapentin; Lidocaine; Opioids; Penciclovir; Post herpetic neuralgia; Pregabalin; Tricyclic antidepressants; Valaciclovir; Varicella; Varicella zoster virus; Zoster

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMITRIPTYLINE; BOTULINUM TOXIN A; CAPSAICIN; CHICKENPOX VACCINE; CIDOFOVIR; CORTICOSTEROID; DESIPRAMINE; DULOXETINE; FAMCICLOVIR; FLUOROURACIL; FOSCARNET; GABAPENTIN; LIDOCAINE; MEASLES VACCINE; METHADONE; METHYLPREDNISOLONE; MORPHINE; MUMPS VACCINE; NORTRIPTYLINE; OXYCODONE; PENCICLOVIR; PREGABALIN; RUBELLA VACCINE; TRAMADOL; VALACICLOVIR; VALPROATE SEMISODIUM; VENLAFAXINE;

ALLODYNIA; ATAXIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN DISEASE; BRAIN VASCULITIS; CEREBELLAR ATAXIA; CHICKENPOX; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENCEPHALITIS; ENCEPHALOMYELITIS; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GUILLAIN BARRE SYNDROME; HEART ARRHYTHMIA; HEPATITIS; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; HYPERGLYCEMIA; IMMUNOCOMPROMISED PATIENT; KERATITIS; KERATOPATHY; KIRISAWA UVEITIS; LATENT PERIOD; MENINGITIS; MYELITIS; NAUSEA; NEPHROTOXICITY; NEURITIS; NEUROPATHIC PAIN; NEUROTOXICITY; NEUTROPENIA; OPHTHALMOPLEGIA; OPTIC NEURITIS; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PAIN; PATHOGENESIS; PERIPHERAL EDEMA; PNEUMONIA; POSTHERPETIC NEURALGIA; REVIEW; SCLERITIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; URINE RETENTION; UVEITIS; VACCINATION; VARICELLA ZOSTER VIRUS; VASCULAR DISEASE; VERTIGO; VIRUS REPLICATION; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIVIRAL AGENTS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; PRODRUGS; TREATMENT OUTCOME;

EID: 67649610071     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902808502     Document Type: Review

References (127)

1. Mandell GL, Douglas RG, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Sixth edition. Philadelphia, Pa.: Elsevier/Churchill Livingstone, 2005
2. Quinlivan M, Breuer J. Molecular and therapeutic aspects of varicella-zoster virus infection. Expert Rev Mol Med 2005;7(15):1-24 •• Detailed but accessible review of molecular biology of VZV infection.
3. Reichelt M, Zerboni L, Arvin AM. Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol 2008;82(8):3971-3983
4. Ku CC, Besser J, Abendroth A, et al. Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005;79(5):2651-2658 (Pubitemid 40270543)
5. Nardone A, de Ory F, Carton M, et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007;25(45):7866-7872 (Pubitemid 47588519)
6. Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007;11(Suppl 2):S43-8 (Pubitemid 350302067)
7. Malavige GN, Jones L, Kamaladasa SD, et al. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS One 2008;3(11):e3789
8. Heininger U, Seward JF. Varicella. Lancet 2006;368(9544):1365-1376
9. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000;182(2):383-390
10. Harger JH, Ernest JM, Thurnau GR, et al. Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 2002;185(4):422-427 (Pubitemid 34142803)
11. Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol 2006;21(4):410-420 • Review of complications of VZV infection in pregnancy.
12. Chickenpox, pregnancy and the newborn. Drug Ther Bull 2005;43(9):69-72
13. Royal College of Obstetricians and Gynaecologists. Chickenpox in Pregnancy. Green-top Guideline No. 13. September 2007.
14. Gershon AA, Chen J, Gershon MD. A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons. J Infect Dis 2008;197(Suppl 2):S61-5 (Pubitemid 351590148)
15. Mckendrick MW, Care CC, Kudesia G, et al. Is VZV reactivation a common cause of unexplained unilateral pain? Results of a prospective study of 57 patients. J Infect 1999;39(3):209-212 (Pubitemid 30099567)
16. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188(9):1336-1344 (Pubitemid 37433704)
17. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352(22):2266-2267 (Pubitemid 40740549)
18. Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol 2007;6(11):1015-1028 •• Review of the neurological complications of VZV infection. (Pubitemid 47562323)
19. Oaklander AL. Mechanisms of pain and itch caused by herpes zoster (shingles). J Pain 2008;9(1 Suppl 1):S10-8 •• Review of the pathogenesis of post-herpetic neuralgia. (Pubitemid 350309522)
20. Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005;252(6):677-686 (Pubitemid 40864042)
21. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998;5(4):209-227 (Pubitemid 28519152)
22. Watson CP, Deck JH, Morshead C, et al. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991;44(2):105-117
23. Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet 1994;343(8913):1648 (Pubitemid 24194838)
24. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004;62(9):1545-1551 (Pubitemid 38608193)
25. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68(15):1178-1182 (Pubitemid 46608464)
26. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006;35(2):132-137
27. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137(1):38-47
28. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197(Suppl 2):S207-15 (Pubitemid 351590173)
29. Binder A, Koroschetz J, Baron R. Disease mechanisms in neuropathic itch. Nat Clin Pract Neurol 2008;4(6):329-337 (Pubitemid 351803615)
30. Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. Pain 2002;96(1-2):9-12 (Pubitemid 34270623)
31. Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008;115(2 Suppl):S3-12 •• Review of ophthalmic complications of VZV infection. (Pubitemid 351173970)
32. Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain 2008;9(1 Suppl 1):S3-9
33. Ahmed AM, Brantley JS, Madkan V, et al. Managing herpes zoster in immunocompromised patients. Herpes 2007;14(2):32-36 (Pubitemid 47556307)
34. Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008;9(1 Suppl 1):S19-30 (Pubitemid 350309523)
35. Peterslund NA, Seyer-Hansen K, Ipsen J, et al. Acyclovir in herpes zoster. Lancet 1981;2(8251):827-830 (Pubitemid 11017551)
36. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147(1):1-11 (Pubitemid 43069091)
37. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9(3):361-381 (Pubitemid 26245616)
38. MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother 2004;53(6):899-901 (Pubitemid 38807628)
39. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39(7):1546-1553
40. Huynh TH, Johnson MW, Comer GM, Fish DN. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol 2008;145(4):682-686
41. Arora A, Mendoza N, Brantley J, et al. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. J Infect Dis 2008;197(9):1289-1295 (Pubitemid 351632760)
42. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36(12):2747-2757
43. Cirelli R, Herne K, McCrary M, et al. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996;29(2-3):141-151 (Pubitemid 26135173)
44. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38(10):2454-2457 (Pubitemid 24304247)
45. Klassen TP, Hartling L, Wiebe N, Belseck EM. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev 2005;(4):CD002980
46. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005;45(5):804-817 (Pubitemid 43181039)
47. Carlon R, Possamai C, Corbanese U. Acute renal failure and severe neurotoxicity following valacyclovir. Intensive Care Med 2005;31(11):1593 (Pubitemid 41598675)
48. Htwe TH, Bergman S, Koirala J. Famciclovir substitution for patients with acyclovir-associated renal toxicity. J Infect 2008;57(3):266-268
49. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997;76(5):369-380
50. Hellden A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother 2006;57(5):945-949
51. Mahad DJ, Hellden A, Jarvis J, et al. Aciclovir induced posterior leucoencephalopathy. J Neurol Neurosurg Psychiatry 2005;76(9):1308-1309 (Pubitemid 41208396)
52. Yang HH, Hsiao YP, Shih HC, Yang JH. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient. Int J Dermatol 2007;46(8):883-884 (Pubitemid 47162798)
53. De Clercq E, Descamps J, Ogata M, Shigeta S. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob Agents Chemother 1982;21(1):33-38
54. Andrei G, Snoeck R, Reymen D, et al. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 1995;14(4):318-329
55. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003;59(1):49-56 (Pubitemid 36773890)
56. Enright AM, Prober C. Antiviral therapy in children with varicella zoster virus and herpes simplex virus infections. Herpes 2003;10(2):32-37 (Pubitemid 37486589)
57. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002;5(2):88-114 • Review of mechanisms and frequency of resistance to antiviral drugs. (Pubitemid 35024271)
58. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993;67(2):1024-1033 (Pubitemid 23032082)
59. Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 1998;178(Suppl 1):S55-7 (Pubitemid 28514271)
60. Harris D, Redhead J. Should acyclovir be prescribed for immunocompetent children presenting with chickenpox? Arch Dis Child 2005;90(6):648-650
61. Balfour HH Jr, Edelman CK, Anderson RS, et al. Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance. Pediatr Infect Dis J 2001;20(10):919-926 (Pubitemid 32952666)
62. Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008;197(Suppl 2):S94-100
63. Wallace MR, Bowler WA, Murray NB, et al. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992;117(5):358-363
64. Mohsen AH, Mckendrick M. Varicella pneumonia in adults. Eur Respir J 2003;21(5):886-891 (Pubitemid 36592302)
65. Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children-a collaborative study. J Pediatr 1982;101(4):622-625
66. Balfour HH Jr, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother 1983;12(Suppl B):169-179 (Pubitemid 14228012)
67. Meszner Z, Nyerges G, Bell AR. Oral acyclovir to prevent dissemination of varicella in immunocompromised children. J Infect 1993;26(1):9-15 (Pubitemid 23064249)
68. Brown SD, White CA, Chu CK, Bartlett MG. Determination of acyclovir in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772(2):327-334 (Pubitemid 34499580)
69. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004;70(4):201-207
70. Tunbridge AJ, Breuer J, Jeffery KJ. Chickenpox in adults - clinical management. J Infect 2008;57(2):95-102
71. Salisbury D, Ramsay M, Noakes K. Immunisation against infectious disease. Third edition. In: David Salisbury, Mary Ramsay, Karen Noakes, editors. London: TSO, 2006
72. Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes 2006;13(3):60-65 (Pubitemid 44955373)
73. McKendrick MW, Lau J, Alston S, Bremner J. VZV infection in pregnancy: a retrospective review over 5 years in Sheffield and discussion on the potential utilisation of varicella vaccine in prevention. J Infect 2007;55(1):64-67 (Pubitemid 46888078)
74. Lin TY, Huang YC, Ning HC, Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997;16(12):1162-1165 (Pubitemid 28006674)
75. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996;125(5):376-383
76. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J 1986;293(6561):1529-1532 (Pubitemid 17016349)
77. Bean B, Braun C, Balfour HH Jr. Acyclovir therapy for acute herpes zoster. Lancet 1982;2(8290):118-121 (Pubitemid 12075575)
78. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44(Suppl 1):S1-26 (Pubitemid 44956795)
79. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997;157(8):909-912 (Pubitemid 28337042)
80. McKendrick MW, Care CD, Ogan P, Wood MJ. A Long Term Follow-Up Study Of Patients Following Herpes Zoster Varicella-Zoster Research Foundation European meeting. Paris 1994
81. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330(13):896-900 (Pubitemid 24094969)
82. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998;178(Suppl 1):S81-4 (Pubitemid 28514277)
83. Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308(24):1448-1453
84. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995;123(2):89-96
85. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004;29(4):248-253 (Pubitemid 38281215)
86. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4(4):241-246 (Pubitemid 24334158)
87. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9(9):863-869 (Pubitemid 30800021)
88. Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998;178(Suppl 1):S76-80 (Pubitemid 28514276)
89. Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19(1):13-22 (Pubitemid 32233797)
90. Wutzler P, De Clercq E, Wutke K, Farber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995;46(3):252-257
91. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110(8):3071-3077
92. Gilden DH, Cohrs RJ, Hayward AR, et al. Chronic varicella-zoster virus ganglionitis-a possible cause of postherpetic neuralgia. J Neurovirol 2003;9(3):404-407 (Pubitemid 36874715)
93. Quan D, Hammack BN, Kittelson J, Gilden DH. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Arch Neurol 2006;63(7):940-942 (Pubitemid 44036293)
94. Acosta EP, Balfour HH Jr. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Chemother 2001;45(10):2771-2774 (Pubitemid 32906669)
95. He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2008;(1):CD005582 (Pubitemid 351807519)
96. British national formulary: London : British Medical Association : Pharmaceutical Society of Great Britain
97. van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006;367(9506):219-224 (Pubitemid 43107666)
98. Pasqualucci A, Pasqualucci V, Galla F, et al. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone. Acta Anaesthesiol Scand 2000;44(8):910-918 (Pubitemid 30682172)
99. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000;343(21):1514-1519 (Pubitemid 30844347)
100. Uscategui T, Doree C, Chamberlain IJ, Burton MJ. Corticosteroids as adjuvant to antiviral treatment in Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008;(3):CD006852 (Pubitemid 351805201)
101. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007;357(16):1598-1607 (Pubitemid 47598402)
102. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2(7):e164 •• Systematic review of efficacy of agents used for treatment of post-herpetic neuralgia. (Pubitemid 46179274)
103. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352(13):1324-1334 •• Demonstration of efficacy of combination therapy in the management of post-herpetic neuralgia. (Pubitemid 40411499)
104. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132(3):237-251 (Pubitemid 350051570)
105. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;(4):CD005454 (Pubitemid 351805150)
106. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57(5):451-462 (Pubitemid 34477042)
107. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280(21):1837- 1842 (Pubitemid 28544424)
108. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94(2):215-224 (Pubitemid 33016615)
109. Gore M, Sadosky A, Tai KS, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther 2007;29(8):1655-1670 (Pubitemid 47500130)
110. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma- aminobutyric acid block secondary hyperalgesia. Brain Res 1998;810(1-2):93-99 (Pubitemid 29003394)
111. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60(8):1274-1283 (Pubitemid 36460982)
112. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109(1-2):26-35 (Pubitemid 38479767)
113. Stacey BR, Barrett JA, Whalen E, et al. Pregabalin for Postherpetic Neuralgia: Placebo-Controlled Trial of fixed and flexible dosing regimens on Allodynia and time to onset of pain relief. J Pain 2008;9(11):1006-1017
114. Kochar DK, Garg P, Bumb RA, et al. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. QJM 2005;98(1):29-34
115. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146
116. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50(6):1837-1841 (Pubitemid 28283261)
117. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59(7):1015-1021
118. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebocontrolled trial. Pain 2003;104(1-2):323-331 (Pubitemid 36835899)
119. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007;(2):CD004846 (Pubitemid 351805933)
120. Lidocaine plasters for postherpetic neuralgia? Drug Ther Bull 2008;46(2):14-16
121. Lin PL, Fan SZ, Huang CH, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med 2008;33(4):320-325
122. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328(7446):991 (Pubitemid 38530371)
123. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7(12):1106-1112
124. Attal N, Ranoux D, Morain F, Bouhassira D. Botulinum Toxin A Induces Direct Analgesic Effects on neuropathic pain: A Randomised Placebo Controlled Study. 12th World Congress on Pain. Glasgow 2008
125. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites-United States, 1995-2005. J Infect Dis 2008;197(Suppl 2):S71-5 • Description of the effect of introducing varicella vaccination on the epidemiology of VZV infection.
126. Lopez AS, Kolasa MS, Seward JF. Status of school entry requirements for varicella vaccination and vaccination coverage 11 years after implementation of the varicella vaccination program. J Infect Dis 2008;197(Suppl 2):S76-81 (Pubitemid 351590151)
127. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-2284 (Pubitemid 40740551)